Persistency rates across weekly and monthly bisphosphonates: results from the IMS health longitudinal prescription database

Weiß, Thomas; Allmen, Heather von; Henderson, Scott C.; Sajjan, Shiva; McHorney, Colleen A.; Markson, Leona E.

doi:10.1016/j.jocd.2007.03.015

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Suboptimal Adherence To Osteoporosis Therapy1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2007

2008

Publication Types

Select...

Article3

Book1

Relationship

Self Cite1

Independent3

Authors

Journals

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…-dosing frequency had little impact on persistence 40 . Fourth, a relatively large percentage of study patients had missing or invalid co-payment information in the database.…”

Section: Discussionmentioning

confidence: 94%

Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills

Weiß

Henderson

McHorney

et al. 2007

Current Medical Research and Opinion

Self Cite

View full text Add to dashboard Cite

show abstract

“…-dosing frequency had little impact on persistence 40 . Fourth, a relatively large percentage of study patients had missing or invalid co-payment information in the database.…”

Section: Discussionmentioning

confidence: 94%

Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills

Weiß

Henderson

McHorney

et al. 2007

Current Medical Research and Opinion

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nearly 50% of all patients receiving weekly alendronate or risedronate remain on treatment for less than 1 year [24,25]. Rates of compliance and persistence also are suboptimal with the use of once-monthly ibandronate [26]. Poor adherence compromises the anti-fracture efficacy of the drugs and contributes to the high cost of adjunctive medical care [27][28][29].…”

Section: Suboptimal Adherence To Osteoporosis Therapymentioning

confidence: 99%

Intravenous zoledronic acid for the treatment of osteoporosis

Lewiecki

2008

Curr Osteoporos Rep

View full text Add to dashboard Cite

Osteoporosis is a preventable disease characterized by loss of bone mineral density, progression to diminished skeletal integrity, extensive bone fragility, and an increased risk of fracture. Morbidity and mortality from osteoporosis are significant, and the public health costs are substantial. Although safe and effective therapy is available, the disease remains underdiagnosed and undertreated. Oral bisphosphonates such as alendronate, risedronate, and ibandronate are the current first-line therapy; however, adherence to treatment is suboptimal, largely because the treatment regimen is difficult to follow. The bisphosphonate zoledronic acid (zoledronate), 5 mg, is administered as an annual 15-minute intravenous infusion for the treatment of postmenopausal osteoporosis, assuring treatment compliance and persistence over the 12-month dosing interval. The drug is safe and generally well tolerated, and provides sustained anti-fracture efficacy at all relevant skeletal sites. Zoledronic acid has the potential to improve clinical outcomes by reducing the risk of fracture in patients with osteoporosis.

show abstract

The Conundrum of Compliance and Persistence with Oral Bisphosphonates for Postmenopausal Osteoporosis

Gold¹,

Solimeo²

2008

Osteoporosis

View full text Add to dashboard Cite

Persistency rates across weekly and monthly bisphosphonates: results from the IMS health longitudinal prescription database

Cited by 4 publications

References 0 publications

Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills

Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills

Intravenous zoledronic acid for the treatment of osteoporosis

The Conundrum of Compliance and Persistence with Oral Bisphosphonates for Postmenopausal Osteoporosis

Contact Info

Product

Resources

About